San Antonio Breast Cancer Symposium®Конференция
Доклады:
-
2022
Dose-expansion study of trastuzumab deruxtecan as monotherapy or combined with pertuzumab in patients with metastatic human epidermal growth factor receptor 2-positive (HER2+) breast cancer in DESTINY-Breast07 (DB-07)
(Стендовый)
-
Авторы:
Hamilton Erika P.,
Jhaveri Komal L.,
Loi Sherene,
Anders Carey K.,
Schmid Peter,
Penkov Konstantin,
Artamonova Elena,
Zhukova Lyudmila,
Stroyakovskiy Daniil,
Doval Dinesh Chandra,
Villanueva Rafael,
Michelini Flavia,
Chandarlapaty Sarat,
Wilson Matt,
Boston Sarice R.,
Konpa Adam,
Mondal Shoubhik,
André Fabrice